Description:
A drug used alone or with other drugs to treat adults with non-small cell lung cancer that has spread and has an abnormal EGFR gene. It is used in patients whose cancer has not been treated with other anticancer therapy or has gotten worse during or after treatment with an EGFR tyrosine kinase inhibitor (a type of anticancer drug) or platinum chemotherapy. It is also being studied in the treatment of other types of cancer. Rybrevant binds to receptors for proteins called EGF and MET, which are found on some types of cancer cells. Blocking these proteins may help keep cancer cells from growing. Rybrevant is a type of bispecific antibody. Also called amivantamab.
